Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance

Pharmacology and Toxicology

Volumn 78, Issue 4, 1996, Pages 203-208

  Catterson, Mark L ^a   Preskorn, Sheldon H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CYTOCHROME P450 ISOENZYME; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

EID: 0029967535     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1996.tb00206.x     Document Type: Review

References (52)

1. Aronoff, G. R., R. F. Bergstrom, S. T. Pottraz, R. S. Sloan, R. L. Wolen & L. Lemberger: Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin. Pharmacol. Therap. 1984, 36, 138-144.
2. Bergstrom, R. F., C. M. Beasley, N. B. Levy, M. Blumenfield & L. Lemberger: The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine. Int. Clin. Psychopharm. 1993, 8, 261-266.
3. Brøsen, K., E. Skjelbo, B. B. Rasmussen, H. E. Poulsen & S. Loft: Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem. Pharmacol. 1993a, 45, 1211-1214.
4. Brøsen, K., J. G. Hansen, K. K. Nielsen, S. H. Sindrup & L. F. Gram: Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur. J. Clin. Pharmacol. 1993b, 44, 349-355.
5. Charney, D. S., H. Miller, J. Licinio & R. Salomon: The pharmacological treatment of depression. In: Textbook of psychopharmacology. Eds.: A. F. Schatzberg, C. B. Nemeroff. American Psychiatric Association Press, Washington, DC, 1995, pp. 575-601.
6. Crewe, H. K., M. S. Lennard, G. T. Tucker, F. R. Woods & R. E. Haddock: The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Brit. J. Clin. Pharmacol. 1992, 34, 262-265.
7. Cusack, B., A. Nelson & E. Richelson: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacol. 1994, 114, 559-565.
8. Dechant, K. L. & S. P. Clissold: Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs 1991, 41, 225-253.
9. DeVane, C. L.: Pharmacokinetics of the newer antidepressants: Clinical relevance. Amer. J. Med. 1994, 97 (suppl. 6A), 13S-23S.
10. DeVries, M. H., M. Raghoebar, I. S. Mathlener & J. van Harten: Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Therap. Drug Monit. 1992, 14, 493-498.
11. Dingemanse, J., T. W. Guentert, E. Moritz & S. A. Eckernas: Pharmacodynamic and pharmacokinetic interactions between fluoxetine and moclobemide. Clin. Pharmacol. Terap. 1993, 53, 178.
12. Doogan, D. P. & V. Caillard: Sertraline: a new antidepressant. J. Clin. Psychiatry 1988, 49 (suppl. 8), 46-51.
13. Eichelbaum, M. & A. S. Gross: The genetic polymorphism of debrisoquine/spartine metabolism - clinical aspects. Pharmacol. Therap. 1990, 46, 377-394.
14. Feighner, J. P. & J. B. Cohn: Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J. Clin. Psychiatry 1985, 46 (3, section 2), 20-25.
15. Henry, J. A.: Overdose and safety with fluvoxamine. Int. Clin. Psychopharmacol. 1991, 6 (suppl. 3), 41-47.
16. Hyttel, J.: Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 1994, 9 (suppl. 1), 19-26.
17. Kaye, C. M., R. E. Haddock, P. F. Langley, G. Mellows, T. C. G. Tasker, B. D. Zussman & W. H. Greb: A review of the metabolism of paroxetine in man. Acta psychiatr. scand. 1989, 80 (suppl. 350), 60-75.
18. Kurtz, D. L., R. F. Bergstrom, M. J. Goldberg & B. J. Cerimele: Drug interaction between sertraline and desipramine or imipramine. J. Clin. Pharmacol. 1994, 34, 1030.
19. Lemberger, L., R. F. Bergstrom, R. L. Wolen, N. A. Farid, G. G. Enas & G. R. Aronoff: Fluoxetine: clinical pharmacology and physiologic disposition. J. Clin. Psychiatry 1985, 46 (3, sect. 2), 14-19.
20. Lydiard, R. B., R. F. Anton & T. Cunningham: Interactions between sertraline and tricyclic antidepressants. Amer. J. Psychiatry 1993, 150, 1125-1126.
21. MacKichan, J. J.: Protein binding drug displacement interactions: fact or fiction? Clin. Pharmacokin. 1989, 16, 65-73.
22. Mahgoub, A., J. R. Idle, L. G. Dring, R. Lancaster & R. L. Smith: Polymorphic hydroxylation of debrisoquine in man. Lancet 1977, 584-586.
23. Milne, R. J. & K. L. Goa: Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991, 41, 450-477.
24. Nemeroff, C. B.: Diagnosis and treatment of depression in medical practice. J. Med. Assoc. Ga. 1993, 82, 461-464.
25. Otton, S. V., D. Wu, R. T. Joffe, S. W. Cheung & E. M. Sellers: Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin. Pharmacol. Therap. 1993, 53, 401-409.
26. Otton, S. V., S. . Ball, S. W. Cheung, T. Inaba & E. M. Sellers: Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine and other 5HT uptake inhibitors. Clin. Pharmacol. Therap. 1994, 55, 141.
27. Overø, K. F., B. Toft, L. Christopherson & J. P. Gylding-Sabroe: Kinetics of citalopram in elderly patients. Psychopharmacol. 1985, 86, 253-257.
28. Overø, K. F.: Kinetics of citalopram in man: plasma levels in patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1982, 6, 311-318.
29. Pentel, P. R., M. L. Bullock & C. L. DeVane: Hemoperfusion for imipramine overdose: elimination of active metabolites. J. Toxicol. Clin. Toxicol. 1982, 19, 239-248.
30. Preskorn, S. H.: Clinical pharmacology of SSRIs: The basis for their optimal use. Professional Communications, Inc., Caddo, Oklahoma, 1995.
31. Preskorn, S. H.: Outpatient management of depression. Professional Communications, Inc., Caddo, Oklahoma, 1994.
32. Preskorn, S. H.: Recent pharmacologic advances in antidepressant therapy for the elderly. Amer. J. med. 1993a, 94 (suppl. 5A), 2-12.
33. Preskorn, S. H.: Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J. Clin. Psychiatry 1993b, 54 9 (suppl.), 14-34.
34. Preskorn, S. H.: Sudden death and tricyclic antidepressants (TCA): a rare adverse event linked to high TCA plasma levels. Nord. J. Psychiatry 1993c, 47 (suppl. 30), 49-56.
35. Preskorn, S. H., J. Alderman, M. Chung, W. Harrison, M. Messig & S. Harris: Pharmacokinetics of desipramine co-administered with sertraline or fluoxetine. J. Clin. Psychopharmacol. 1994, 14, 90-98.
36. Preskorn, S. H. & G. A. Fast: Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J. Clin. Psychiatry 1991, 52, 23-33.
37. Preskorn, S. H. & G. S. Jerkovich: Central nervous system toxicity of tricyclic antidepressants. phenomenology, course, risk factors, and role of therapeutic drug monitoring. J. Clin. Psychopharmacol. 1990, 10, 88-95.
38. Preskorn, S. H. & R. D. Magnus: Inhibition of hepatic P450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol. Bull. 1994, 30, 251-259.
39. Raghoebar, M. & H. Roseboom: Kinetics of fluvoxamine in special populations. Poster presented at the "Symposium on Variability in pharmacokinetics and drug responses". Gothenburg, October 3-5, 1988.
40. Richelson, E.: Pharmacology of antidepressants Characteristics of the ideal drug. Mayo Clin. Proc. 1994, 69, 1069-1081.
41. Sindrup, S. H., K. Brøsen & L. F. Gram: Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism. Clin. Pharmacol. Therap. 1992, 51, 288-295.
42. Sindrup, S. H., K. Brøsen, M. G. J. Hansen, T. Aaes-Jorgensen, K. F. Overø & L. F. Gram: Pharmacokinetics of citalopram in relation to the sparteine and mephenytoin oxidation polymorphisms. Ther. Drug Monit. 1993, 15, 11-17.
43. Skjelbo, E. & K. Brøsen: Inhibitors of imipramine metabolism by human liver microsomes. Brit. J. Clin. Pharmacol. 1992, 34, 256-261.
44. Smith, R. L., J. R. Idle, A. A. Mahgoub, T. P. Sloan & R. Lancaster: Genetically determined defects of oxidation at carbon centers of drugs. Lancet 1978, 943-944.
45. Spina, E., A. M. Pollicino, A. Avenoso, G. M. Campo, E. Perucca & A. P. Caputi: Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther. Drug Monit. 1993, 15 (3), 243-246.
46. Sternbach, H.: Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988, 850-851.
47. van Harten, J.: Clinical pharmacokinetics of selective serotonin reuptake inhibitors Clin. Pharmacokin. 1993, 24, 203-220.
48. Vaughn, D. A.: Interaction of fluoxetine with tricyclic antidepressants. Amer. J. Psychiatry 1988, 145, 1478.
49. von Moltke, L. L., D. J. Greenblatt, J. S. Harmatz & R. I. Shader: Cytochromes in psychopharmacology. J. Clin. Psychopharmacol. 1994, 14, 1-4.
50. von Moltke, L. L., D. J. Greenblatt, M. H. Court, S. X. Duan, J. S. Harmatz & R. I. Shader: Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other serotonin-reuptake-inhibitor antidepressants. J Clin. Psychopharmacol. 1995, 15, 125-131.
51. von Moltke, L. L., D. J. Greenblatt, M. M. Cotreau-Bibbo, S. X. Duan, J. S. Harmatz & R. I. Shader: Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J. Pharmacol. Exp. Therap. 1994, 268, 1278-1283.
52. Wilner, K. D., G. Apseloff, N. Gerber, E. B. Henry, J. D. Lazar & L. M. Tremaine: Absence of a biologically meaningful effect of sertraline on the pharmacodynamics and protein binding of warfarin. Clin. Pharmacokinet. 1995, in press.